• Production of the Johnson & Johnson vaccine in Baltimore blocked

  • Covid-19, Ema green light for the Johnson & Johnson vaccine: "Rare events, more benefits than risks"

  • Johnson & Johnson, Ema's opinion is awaited today

Share

20 April 2021The Technical-Scientific Commission (CTS) of the Italian Medicines Agency (Aifa) meets today for the evaluation of the Johnson & Johnson anti-Covid vaccine, after the European Medicines Agency (Ema) has recognized "possible" links cause and effect between the vaccine and the "very rare" events of cerebral thrombosis that occurred in the US.



The vaccine had been suspended by the same company for the vaccination campaign in Europe after the reporting of adverse events in the USA.